Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

Ritlecitinib works well and is safe for treating alopecia areata.

Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.

Chemoprevention can significantly lower cancer risks and needs more research and collaboration.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.

Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Sacituzumab Tirumotecan shows promise in treating gynecologic cancers with manageable side effects.

A combination of desogestrel and ethinyl oestradiol effectively reduces hair growth in hirsute women.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Ixekizumab has known and some unexpected side effects.

Incretin-based drugs for obesity often cause gastrointestinal issues, with tirzepatide having the most reports.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.

5α-reductase inhibitors may lower the risk of death from bladder cancer.

17β-estradiol can reduce inflammation in the skin.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.